Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTITUDE-4: Cilta-cel vs Standard Therapy in Relapsed/Refractory Multiple Myeloma
NCT04181827Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2020
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 16
01
Overview
A Phase 3 trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jun 2020; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04181827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181827.